Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis
Gaballah, Ahmed; Shafik, Amr; Elhusseiny, Khaled; Ashraf, Mai;
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major toxicity that requires treatment
modification or cessation and worsens patients’ quality of life. Its incidence is 30–40%. Occurrence and severity depend
on treatment- and patient-related factors. The symptoms are self-limiting with recovery rate about 50%. Methods:
This retrospective analysis took place in our chemotherapy unit. We included patients treated between January 2014
and December 2015. Results: 250 patients were eligible. 53 received paclitaxel, 78 received docetaxel, 64 received
cisplatin and 55 received oxaliplatin. Mean age was 50.11 years. Frequency of CIPN was 46.8% (Grade I 70.9%, GII
24.7%, GIII 4.4%). It was 74% with oxaliplatin, 73.5% with paclitaxel, 35.9% with cisplatin and 17.9% with docetaxel.
After median of 6 months 24% of patients recovered completely. No significant correlation between occurrence of
CIPN and age (p = 0.781), while was significant with cisplatin (p = 0.043). Diabetic patients had higher incidence (p
= 0.007). With cisplatin, median cumulative dose of 450 mg/m2 and ≥ 6 cycles had higher incidence of CIPN (p 0.006
and 0.010; respectively). With oxaliplatin, none was correlated with CIPN frequence. With paclitaxel, CIPN was more
frequent if ≥ 4 cycles were received (p = 0.005). With docetaxel, > 4 cycles or cumulative dose ≥ 360 mg/m2 had higher
occurrence of GII CIPN (p < 0.001 for both). Conclusion: CIPN is common problem that affects patients’ quality of
life and leads to treatment interruption. There are many factors affecting its incidence and severity.
modification or cessation and worsens patients’ quality of life. Its incidence is 30–40%. Occurrence and severity depend
on treatment- and patient-related factors. The symptoms are self-limiting with recovery rate about 50%. Methods:
This retrospective analysis took place in our chemotherapy unit. We included patients treated between January 2014
and December 2015. Results: 250 patients were eligible. 53 received paclitaxel, 78 received docetaxel, 64 received
cisplatin and 55 received oxaliplatin. Mean age was 50.11 years. Frequency of CIPN was 46.8% (Grade I 70.9%, GII
24.7%, GIII 4.4%). It was 74% with oxaliplatin, 73.5% with paclitaxel, 35.9% with cisplatin and 17.9% with docetaxel.
After median of 6 months 24% of patients recovered completely. No significant correlation between occurrence of
CIPN and age (p = 0.781), while was significant with cisplatin (p = 0.043). Diabetic patients had higher incidence (p
= 0.007). With cisplatin, median cumulative dose of 450 mg/m2 and ≥ 6 cycles had higher incidence of CIPN (p 0.006
and 0.010; respectively). With oxaliplatin, none was correlated with CIPN frequence. With paclitaxel, CIPN was more
frequent if ≥ 4 cycles were received (p = 0.005). With docetaxel, > 4 cycles or cumulative dose ≥ 360 mg/m2 had higher
occurrence of GII CIPN (p < 0.001 for both). Conclusion: CIPN is common problem that affects patients’ quality of
life and leads to treatment interruption. There are many factors affecting its incidence and severity.
Other data
Title | Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis | Authors | Gaballah, Ahmed ; Shafik, Amr; Elhusseiny, Khaled; Ashraf, Mai | Keywords | CIPN;Neuropathy;Egypt | Issue Date | 24-Aug-2018 | Journal | Asian Pacific Journal of Cancer Prevention | DOI | 10.22034/APJCP.2018.19.8.2223 | PubMed ID | 30139229 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.